Pharma firm Dr Reddy’s Laboratories Limited and Nasdaq-listed Integra LifeSciences Holdings Corporation today announced an exclusive distribution agreement to market and distribute dural regeneration matrices for use in patients in India.
Under the agreement, Dr Reddy’s will market and distribute DuraGen Plus and Suturable DuraGen dural regeneration matrices for use in patients in the country, a statement issued here said.
The DuraGen product line offers duraplasty solutions meant for the repair of the dura mater. Dura mater is a thick membrane that surrounds the brain and spinal cord, and contains the cerebrospinal fluid (CSF).
“We are delighted to partner with Integra LifeSciences. With the launch of DuraGen, we look forward to building our presence in the segment of regenerative technologies and making a difference to the lives of patients undergoing neurosurgery,” Dr Reddy’s Laboratories Executive Vice President and Head of Emerging Markets & India Business M V Ramana said.
“Our market-leading DuraGen products have helped more than one million patients worldwide. This collaboration will allow us to continue to expand patient access globally and provide innovative regenerative technology solutions to neurosurgeons and patients in India,” Integra LifeSciences Chief Financial Officer and Corporate Vice President Glenn Coleman said.
DuraGen Plus Dural Regeneration Matrix is indicated as a dural substitute for the repair of dura mater. It offers a simple technique for precise placement of the matrix as an onlay graft in cranial and spinal procedures, and easily conforms to the complex surfaces of exposed neural tissue.
{{/usCountry}}DuraGen Plus Dural Regeneration Matrix is indicated as a dural substitute for the repair of dura mater. It offers a simple technique for precise placement of the matrix as an onlay graft in cranial and spinal procedures, and easily conforms to the complex surfaces of exposed neural tissue.
{{/usCountry}}It provides effective protection against CSF leakage with sutureless closure and is fully resorbed and replaced by native tissue with complete dural closure.
Integra’s DuraGen products have been implanted in more than 1.8 million patients worldwide to effect dural closure following neurosurgical procedures. Integra manufactures the DuraGen family of products based on its proprietary Ultra Pure Collagen technology platform, the release said.